Document:

Exhibit 10.66

 

TRANSITION AGREEMENT AND STOCK PLEDGE

 

This Transition Agreement
and Stock Pledge (this “Agreement”) is made as of August            
, 2007, by and between PHOENIX MANAGEMENT COMPANY, LLC, a Michigan limited
liability company (“Phoenix”), AMERICAN ONCOLOGIC ASSOCIATES OF MICHIGAN, P.C.,
a Michigan professional corporation (the “PC”); and MICHAEL J. KATIN, M.D. (the
“Current Shareholder”).

 

RECITALS:

 

The following Recitals are
hereby incorporated in this Agreement:

 

A.                                   The PC and
Phoenix, as a successor in interest to Pontiac Investment Associates, have
entered into a Business Operations and Support Services Agreement, dated August
19, 2000 (as amended, the “BOA”), for the provision of certain administrative
and billing services to the PC in connection with the PC’s provision of
radiation therapy services in Michigan (the “State”).

 

B.                                     The Current
Shareholder owns all of the issued and outstanding shares of the PC’s stock.

 

C.                                     The parties
hereto believe it to be in their best interest to make provision for the future
disposition of all of the shares of the capital stock of the PC whether
currently issued and outstanding or issued at any time (the “Shares”).

 

D.                                    The Current
Shareholder may desire to issue or transfer Shares to qualified shareholders
satisfactory to and approved by Phoenix (together with the Current Shareholder
the “Shareholders”), upon such Shareholders becoming licensed to practice
medicine in the State, and provided that each or all, as applicable, execute an
agreement in substantially the same form as this Agreement.

 

E.                                      The Current
Shareholder desires to pledge the Shares to secure the covenants made in this
Agreement, and Phoenix desires to accept such security interest.

 

NOW,
THEREFORE, for and in consideration of the mutual agreements, terms, covenants
and conditions contained herein and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties agree
as follows:

 

1.                                       Definitions.

 

1.1.                              “Shareholder
Event of Transfer” means any one or more of the following events:

 

(a)                                  The transfer of
or attempt to transfer any Shares by any Shareholder, including any sale,
assignment, conveyance, gift or any other form of disposition or transfer,
voluntary or involuntary, including transfers by bequest or inheritance, not
permitted by the terms of this Agreement;

 

(b)                                 Loss of a
Shareholder’s license to practice radiation therapy in the State for any
reason;

 

(c)                                  A Shareholder
is adjudicated incompetent by any court of law;

 

(d)                                 A Shareholder
becomes insolvent by reason of an inability to pay debts as they mature; files
a petition in bankruptcy, reorganization or similar proceeding under the
bankruptcy laws of the United States or has such a petition filed against a
Shareholder which is not discharged within thirty (30) days; has a receiver or
other custodian, permanent or temporary, appointed for the business, assets

 

 

or property of a
Shareholder; has his bank accounts, property or accounts attached; has
execution levied against business or property of a Shareholder; makes an
assignment for the benefit of creditors; or a Shareholder has any Shares
attached or levied upon for the payment of debts;

 

(e)                                  Any breach of
any of the provisions of this Agreement by a Shareholder; or

 

(f)                                    For any reason
a Shareholder no longer meets the qualifications to be a shareholder of a
professional corporation in the State.

 

1.2.                              “PC Event of
Transfer” means any one of the following events:

 

(a)                                  There is a
Default (as hereinafter defined) under the BOA by the PC which is not cured
within any applicable cure periods stated in the BOA;

 

(b)                                 Any breach of
the provisions of this Agreement by the PC; or

 

(c)                                  The occurrence
of an Shareholder Event of Transfer where there is only one Shareholder.

 

1.3.                              “Transferee”
means a physician licensed to practice radiation therapy in the State, or a
professional corporation qualified to practice radiation therapy in the State,
chosen by Phoenix.

 

2.                                       Grant of
Security Interest. Each Shareholder grants to Phoenix a security interest
in the Shares to secure the Shareholder’s obligations set forth in Section 3.

 

3.                                       General
Restriction on Transfer. No Shareholder shall sell, transfer,
encumber, pledge, will, or otherwise dispose of such Shareholder’s Shares, or
allow such Shareholder’s Shares to pass under the intestate laws or by
operation of law, except as permitted by this Agreement. If any Shares or any
rights therein are transferred contrary to this Agreement, Phoenix retains a
security interest in such Shares and in the proceeds of such disposition.

 

4.                                       Conditional
Agreement to Transfer Stock. All Shareholders shall
immediately transfer the Shares in accordance with the terms of this Agreement
in consideration for the payment of the Purchase Price (as defined in and
determined in accordance with Section 7 hereof) upon the occurrence of a PC
Event of Transfer or upon the occurrence of a Shareholder Event of Transfer.

 

5.                                       Transfers by
Shareholders. If a Shareholder Event of Transfer occurs, then
Phoenix, the PC and/or any Shareholder (or such Shareholder’s legal
representative or a lien creditor of such Shareholder exercising its remedies
with respect to such Shareholder) shall provide the other parties hereto with
written notice thereof (the “Notice”).

 

5.1.                              During the
period commencing on the date the Notice is given and ending thirty (30) days
thereafter (the “Shareholders’ Option Period”), the Shareholders, other than
the Shareholder who is subject to the Shareholder Event of Transfer (the “Transferring
Shareholder”), shall, in relative proportion to the respective ownership of
Shares of such Shareholders who desire to exercise their option, have the
exclusive right (but not the obligation) to acquire all or a portion of the
Transferring Shareholder’s Shares at the pro rata Purchase Price determined
pursuant to Section 7 hereof. Said Shareholders may exercise this option by
delivering, within the Shareholders’ Option Period, to the Transferring
Shareholder, Phoenix and the PC, a written notice stating that said
Shareholders have elected to acquire all or such specified number or proportion
of the Transferring Shareholder’s Shares not later than ninety (90) days after
the date of the Notice. If not all Shareholders (other than the

 

2

 

Transferring Shareholder)
elect to acquire the Transferring Shareholder’s Shares, the Shareholders that
have elected to acquire the Transferring Shareholder’s Shares may acquire the
Transferring Shareholder’s Shares in relative proportion to their respective
ownership of Shares (not counting Shares held by the Transferring Shareholder
or by Shareholders who have not elected to acquire the Transferring Shareholder’s
Shares).

 

5.2.                              If the
Shareholder’s Option Period shall have expired without the election by any of
the Shareholders to acquire any and all of the Transferring Shareholder’s
Shares, then, for either a period of thirty (30) days commencing thirty-one
(31) days after the date of the Notice, the PC shall have the exclusive right
(but not the obligation) to acquire all of the Transferring Shareholder’s
Shares for the Purchase Price. The PC may exercise its option by delivering,
within the PC Option Period, to each of the Shareholders and Phoenix, a written
notice stating that the PC has elected to acquire all or such specified number
or proportion of the Transferring Shareholder’s Shares no later than ninety
(90) days after the date of the Notice.

 

5.3.                              If, but only
if, the Shareholder’s Option Period and the PC Option Period shall have expired
without the election by any of the Shareholders (other than the Transferring
Shareholder) or the PC to acquire all of a Transferring Shareholder’s Shares,
then Phoenix shall designate a Transferee to purchase the Shares which are not
being purchased pursuant to Sections 5.1 and 5,2, above, for an amount equal to
the Purchase Price.

 

5.4.                              The provisions
of this Section 5 shall not apply if there is only one Shareholder.

 

6.                                       Transfer on PC
Event of Transfer. If a PC Event of Transfer occurs, Phoenix shall
designate a Transferee to purchase all of the Shares of the PC for an amount
equal to the Purchase Price within thirty (30) days of Management Service’s
discovery of the occurrence of a PC Event of Transfer.

 

7.                                       Payment of
Purchase Price. The purchase price for any transfer of the Shares
(the “Purchase Price”) shall be an amount equal to the fair market value of the
Shares as of the date of the transfer, determined by the accounting firm of
Ernst &  Young, LLP (or any
successor thereto) acting through the personnel at its office in Tampa,
Florida, if that firm is willing to make the determination; or, if not, any
nationally recognized firm of independent certified public accountants chosen
by Phoenix. Any determination of the fair market value of the Shares by such firm
shall be deemed a final determination of the fair market value as of the
determination date and shall be conclusive upon all parties for purposes of
this Agreement as a commercially reasonable price. The Purchase Price shall be
payable in cash, by cashier’s check, or by a promissory note within thirty (30)
days after receipt of the accounting firm’s Purchase Price determination. If
payment is made by a promissory note, such note shall be payable over three (3)
years in equal monthly installments of principal and interest and shall bear
interest, with such interest to accrue at eight percent (8%) per annum.

 

8.                                       Commercially
Reasonable Disposition. The parties acknowledge that it would be
impossible to realize a commercially reasonable price in the event of the
disposition of Shares by public sale and very difficult to do so by private
sale, except on the terms and conditions set forth herein. Therefore, the
parties acknowledge that a disposition of the Shares pursuant to the terms of
this Agreement is a commercially reasonable disposition. The parties further
acknowledge and agree that the determination of the Purchase Price under Section
7 is a commercially reasonable method of determining the Purchase Price and
that they will be bound by such Purchase Price determination.

 

9.                                       Term. This
Agreement shall continue for as long as the BOA and any renewals thereof are in
effect.

 

3

 

10.                                 Representations
and Warranties. The PC and each of the Shareholders represent and
warrant the following:

 

10.1.                        No
Contravention. There is no provision of any agreement to which
the PC or any Shareholder is a party or of any law that would be contravened by
the execution, delivery, or performance of this Agreement. The PC and each Shareholder’s
name and the information contained in the Recitals hereto are correct. There
are no outstanding or authorized options, warrants, purchase rights,
subscription rights, conversion rights, exchange rights, or other contracts or
commitments that could require the PC to issue, sell, or otherwise cause to
become outstanding any of its capital stock. There is no litigation nor are
there any proceedings by any public body, agency, or authority presently
pending or threatened against the PC or any Shareholder, the outcome of which
might materially and adversely affect the continued operations of the PC.

 

10.2.                        Shares. Each
Shareholder has good title to the Shares, free and clear of all claims,
charges, liens, encumbrances, restrictions, options, calls and defects of any
kind or nature whatsoever, except for the security interest granted hereby. No
other person, entity, or governmental authority has or claims any lien or other
interest in the Shares. No adverse financing statements are on file concerning
the Shares and there is no litigation nor are there any proceedings by any
public body, agency, or authority presently pending or threatened against any
Shareholder, the outcome of which might materially and adversely affect the
Collateral.

 

10.3.                        Survival of
Representations and Warranties. All representations,
covenants and warranties set forth herein shall survive the execution and
delivery of this Agreement.

 

11.                                 Affirmative
Covenants.

 

11.1.                        Application to
Future Shares. This Agreement shall apply to all Shares now owned
or hereafter acquired whether such acquisition be the result of purchase, stock
dividend, split-up, recapitalization, issuance by the PC of additional shares
of capital stock or otherwise.

 

11.2.                        No Agency and
Defense Against Claims. Nothing in this Agreement shall make any
Shareholder an agent of Phoenix for any purpose whatsoever. Each Shareholder
shall defend the Shares against all claims, demands, and defenses affecting
Phoenix’s security interest in the Shares, regardless of merit, and shall hold
Phoenix harmless therefrom, including, without limitation, holding Phoenix
harmless from all attorneys’ fees and other litigation expenses arising out of
any such claims, demands, or defenses.

 

11.3.                        Disposition and
Issuances of the PC’s Common Stock. The PC shall not, and
during the term of this Agreement each Shareholder shall not cause the PC to,
issue, sell or otherwise cause to be outstanding any additional capital stock,
except for: (a) sales of such stock made to approved Shareholders; (b) the
transfer without consideration of any of the Shares to a revocable trust
created by a Shareholder, provided that any and all trustees of such trust
first agrees in writing to hold Shares so transferred subject to this
Agreement; and (c) the transfer of Shares as permitted by the terms of this
Agreement.

 

12.                                 Custody and
Handling of Collateral and Records.

 

12.1.                        Protection of
Secured Party’s Security Interest. Upon execution of this
Agreement, each Shareholder shall give Phoenix the certificate(s) representing
such Shareholder’s Shares duly endorsed in blank or, if not endorsed in blank,
each Shareholder shall give Phoenix a duly executed stock power in blank.

 

4

 

12.2.                        Restrictive
Legend. Each certificate representing Shares of the PC shall be marked with a
legend substantially in the following form:

 

The right to sell, transfer
or encumber the shares represented by this certificate is restricted under the
terms of Transition Agreement and Stock Pledge dated August           , 2007, to which the PC is a party.
The PC will mail a copy of said Agreement to any shareholder without charge
within five (5) days after receipt of written request therefore.

 

13.                                 Default and
Remedies.

 

13.1.                        Remedies Upon
Default. Upon the occurrence of any breach of any of the terms of this
Agreement by the PC or any or all of the Shareholders (a “Default”), Phoenix
shall have the right and option to: (i) immediately send notice to all parties
hereto of a Shareholder Event of Transfer or a PC Event of Transfer, as
applicable, to cause a transfer of Shares pursuant to Section 5 or Section 6
hereof, subject to a subsequent determination of the Purchase Price, and (ii) exercise
any other remedies and/or rights available to Phoenix as a secured party under
law or equity. Without limiting the foregoing, Phoenix shall be entitled upon
any breach or threatened breach of this Agreement to the granting of a
temporary restraining order, a temporary or permanent injunction, or any other
equitable remedy which may then be available without further notice.

 

13.2.                        Construction of
Rights and Remedies and Waiver of Notice and Consent. The rights
and remedies of Phoenix herein expressly specified are cumulative and not
exclusive of other contractual, common law or statutory rights and remedies
which secured parties may have, including without limitation, all rights and
remedies of a secured creditor under applicable law. Phoenix shall be under no
duty to exercise or withhold the exercise of any of its rights and remedies
provided hereunder or otherwise. No omission or delay by Phoenix in exercising
any such right or remedy shall operate as a waiver or partial waiver of any
such right or remedy thereof, nor shall any single or partial exercise of any such
right or remedy preclude any other or further exercise thereof or the exercise
of any other right or remedy.

 

14.                                 Miscellaneous.

 

14.1.                        Notices. If at any
time after the execution of this Agreement, it shall become necessary or
convenient for one of the parties to serve any notice, demand or communication
upon the other parties, such notice, demand, or communication shall be in
writing and shall be served personally, by nationally recognized overnight
courier which provides confirmation of delivery, or by depositing the same in
the United States mail, registered or certified, return receipt requested,
postage prepaid and to such address as each party may have furnished to the
other parties in writing as the place for the service of notice. Any notice so mailed
shall be deemed to have been given three (3) days after the same has been
deposited in the United States mail; when delivered if the same has been given
personally; or the next business day if the same has been delivered to a
nationally recognized overnight courier service.

 

14.2.                        Governing Law. This
Agreement shall be construed and interpreted under the laws of the State of
Florida.

 

14.3.                        Binding Effect. This
Agreement shall be binding upon each of the parties hereto and their respective
heirs, successors, and permitted assigns. Neither the PC nor any Shareholder
may assign this Agreement without the prior written permission of Phoenix.

 

14.4.                        Amendment. This
Agreement may be amended, but only by a written amendment signed by all parties
hereto.

 

5

 

14.5.                        Severability. If any
provision of this Agreement or the application of any provision to any party or
circumstance shall be adjudged invalid or unenforceable to any extent, the
remainder of this Agreement and the application of the provision to any other
party or circumstance shall not be affected thereby. Each provision of this
Agreement shall be valid and enforceable to the fullest extent permitted by
law.

 

14.6.                        Headings. The headings
in this Agreement are for convenience of reference only and shall not be used
in interpreting this Agreement.

 

14.7.                        Number; Gender. Where
appropriate, the number of all words in this Agreement shall be both singular
and plural and the gender of all pronouns shall be masculine, feminine, neuter,
or any combination thereof.

 

IN WITNESS
WHEREOF, the parties have executed this Agreement as of the
date first set forth above.

 

	
   

  	
  AMERICAN ONCOLOGIC
  ASSOCIATES OF

  MICHIGAN, P.C.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Michael J. Katin

  
	
   

  	
  Name:

  	
  Michael
  J. Katin, M.D.

  
	
   

  	
  Title:

  	
  President

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  PHOENIX MANAGEMENT
  COMPANY, LLC

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ David N. T. Watson

  
	
   

  	
  Name:

  	
  David N. T. Watson

  
	
   

  	
  Title:

  	
  Vice-President

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Michael J. Katin

  
	
   

  	
  Michael
  J. Katin, M.D.

  

 

6Exhibit 10.67

 

TRANSITION AGREEMENT AND STOCK PLEDGE

 

This Transition Agreement
and Stock Pledge (this “Agreement”) is made as of June 1, 2005, by and
between Massachusetts Oncology Services, P.C., a Massachusetts professional
corporation (“Manager); New England Radiation Therapy Manager, Inc., a
Massachusetts corporation (the “P.C.”); Daniel E. Dosoretz, M.D. and Michael
Katin, M.D. (the “Current Shareholders”).

 

RECITALS

 

A.                     The P.C. and
Manager have entered into a Management Services Agreement, effective June 1,
2005 (the “MSA”), pursuant to which the P.C. engaged Manager to provide certain
administrative services in connection with the P.C.’s provision of medical
services in Massachusetts (the “State”).

 

B.                       The Current
Shareholders own all of the issued and outstanding shares of the captive stock
of the P.C.

 

C.                       The parties
hereto believe it to be in their best interest to make provision for the future
disposition of all of the shares of the capital stock of the P.C. whether
currently issued and outstanding or issued at any time hereafter (the “Shares”).

 

D.                      The Current
Shareholders may desire to issue or transfer Shares to qualified shareholders
satisfactory to and approved by Manager (together with the Current Shareholder
the “Shareholders”), upon such Shareholders becoming licensed to practice
medicine in the State, and provided that each or all, as applicable, execute an
agreement in substantially the same form as this Agreement.

 

E.                        The Current
Shareholders desire to pledge the Shares to secure the covenants made in this
Agreement, and Manager desires to accept such security interest.

 

NOW, THEREFORE, for and in
consideration of the mutual agreements, terms, covenants and conditions
contained herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.                          Definitions.

 

1.1                   “Shareholder
Event of Transfer” means any one or more of the following events:

 

(a)                     The transfer of
any Shares by any Shareholder, including any sale, assignment, conveyance, gift
or any other form of disposition or transfer, voluntary or involuntary,
including transfers by bequest or inheritance, without the approval of Manager;

 

(b)                    Loss of a
Shareholder’s license to practice medicine in the State for any reason;

 

(c)                     A Shareholder
is adjudicated incompetent;

 

 

(d)                    A Shareholder
becomes insolvent by reason of an inability to pay debts as they mature; files
a petition in bankruptcy, reorganization or similar proceeding under the
bankruptcy laws of the United States or has such a petition filed against a
Shareholder which is not discharged within thirty (30) days; has a receiver or
other custodian, permanent or temporary, appointed for the business, assets or
property of a Shareholder; has bank accounts, property or accounts of a
Shareholder’s attached; has execution levied against business or property of a
Shareholder; makes an assignment for the benefit of creditors; or a Shareholder
has any Shares attached or levied upon for the payment of debts;

 

(e)                     Any
representation or covenant contained in this Agreement is breached by a
Shareholder; or

 

(f)                       For any reason
a Shareholder no longer meets the qualifications to be a shareholder of a
professional corporation in the State.

 

The parties hereby agree and
acknowledge that any non-breaching Shareholders may cure a Shareholder Event of
Transfer by purchasing all of the Shares of a Shareholder who has caused any of
such Shareholder Events of Transfer to occur, within thirty (30) days of such
Event.

 

1.2                   “P.C. Event of
Transfer” means any one of the following events:

 

(a)                     There is a
Default (as defined in Section 12) under the MSA by the P.C. which is not
cured within any applicable cure periods stated in the MSA; or

 

(b)                    Any
representation or covenant contained in this Agreement is breached by the P.C.

 

1.3                   “Transferee”
means a physician licensed to practice medicine in the State, or a professional
corporation qualified to practice medicine in the State, chosen by Manager.

 

2.                          Grant of
Security Interest. Each Shareholder grants to Manager a security
interest in the Shares to secure the Shareholder’s obligations set forth in Section 3.

 

3.                          General
Restriction on Transfer. No Shareholder shall sell, transfer,
encumber, pledge, will, or otherwise dispose of such Shareholder’s Shares, or
allow such Shareholder’s Shares to pass under the intestate laws or by
operation of law, except as provided in this Agreement. If any Shares or any
rights therein are transferred contrary to this Agreement, Manager retains a
security interest in such Shares and in the proceeds of such disposition.

 

4.                          Conditional
Agreement to Transfer Stock. Except where the
non-breaching Shareholders cure a Shareholder Event of Transfer as provided in Section 1.1
above, all Shareholders shall immediately transfer the Shares as set forth in
this Agreement for the Purchase Price set forth in Section 7 below upon
the occurrence of a P.C. Event of Transfer or upon the occurrence of a
Shareholder Event of Transfer.

 

5.                          Transfers by
Shareholders. If a Shareholder Event of Transfer occurs, then
the P.C. and any Shareholder aware of such Shareholder Event of Transfer, the

 

2

 

Shareholder’s legal
representative or a lien creditor of the Shareholder exercising its remedies
with respect to such Shareholder (in any case, the “Transferring Shareholder”)
shall give the P.C., Manager and each of the other Shareholders written notice
thereof within five (5) days of such Shareholder Event of Transfer (the “Notice”).

 

5.1                   During the
period commencing on the date the Notice is given and ending thirty (30) days
thereafter (the “Shareholders’ Option Period”), the Shareholders other than the
Transferring Shareholder shall, in relative proportion to the respective
ownership of Shares of such Shareholders who desire to exercise their option,
have the exclusive right (but not the obligation) to acquire all or a portion
of the Transferring Shareholder’s Shares at the pro rata Purchase Price
determined pursuant to Section 7 hereof. Said Shareholders may exercise
this option by delivering, within the Shareholders’ Option Period, to the
Transferring Shareholder, Manager and the P.C. a writing stating that said
Shareholders have elected to acquire all or such specified number or proportion
of the Transferring Shareholder’s Shares not later than ninety (90) days after
the date of the Notice. If not all Shareholders (other than the Transferring
Shareholder) elect to acquire the Transferring Shareholder’s Shares, the
Shareholders that have elected to acquire the Transferring Shareholder’s Shares
may acquire the Transferring Shareholder’s Shares in relative proportion to
their respective ownership of Shares (not counting Shares held by the
Transferring Shareholder or by Shareholders who have not elected to acquire the
Transferring Shareholder’s Shares).

 

5.2                   If the
Shareholder’s Option Period shall have expired without the election by any of
the Shareholders to acquire any and all of the Transferring Shareholder’s
Shares, then, for a period of thirty (30) days commencing thirty-one (31) days
after the date of the Notice (the “P.C, Option Period”), the P.C. shall have
the exclusive right (but not the obligation) to acquire all or a portion the
Transferring Shareholder’s Shares at the pro rata Purchase Price. The P.C. may
exercise its option by delivering, within the P.C. Option Period, to each of
the Shareholders and Manager a writing stating that the P.C. has elected to
acquire all or such specified number or proportion of the Transferring Shareholder’s
Shares no later than ninety (90) days after the date of the Notice.

 

5.3                   If, but only
if, the Shareholder’s Option Period and the P.C. Option Period shall have
expired without the election by any of the Shareholders other than the
Transferring Shareholder or the P.C. to acquire all of a Transferring
Shareholder’s Shares, then Manager shall designate a Transferee to purchase the
Shares which are not being purchased pursuant to Sections 5.1 and 5.2 above.

 

6.                          Transfer on
P.C. Event of Transfer. If a P.C. Event of Transfer occurs, Manager
shall designate a Transferee to purchase all of the Shares of the P.C. within
thirty (30) days of Management Service’s discovery of the occurrence of a P.C.
Event of Transfer.

 

7.                          Payment of
Purchase Price. The purchase price for any transfer of the Shares
(the “Purchase Price”) shall be an amount equal to the fair market value of the
Shares as of the date of the transfer, determined by the accounting firm of
Ernst & Young, LLP (or any successor thereto) acting through the
personnel at its office in Tampa, Florida, if that firm is willing to make the
determination; or, if not, any nationally recognized firm of independent
certified public accountants agreed to by Manager and the P.C. Any
determination of the book

 

3

 

market value of the Shares
by such firm shall be deemed a final determination of the book market value as
of the determination date and shall be conclusive upon all parties for purposes
of this Agreement as a commercially reasonable price. The Purchase Price shall
be payable in cash, by cashier’s check, or by a promissory note within thirty
(30) days after receipt of the accounting firm’s Purchase Price determination.
If payment is made by a promissory note, such note shall be payable over three
in thirty-six equal monthly installments of principal and interest and shall
bear interest at the rate of eight percent (8%) per annum.

 

8.                          Commercially
Reasonable Disposition. The parties acknowledge that it would be impossible
to realize a commercially reasonable price in the event of the disposition of
the pledged stock by public sale and very difficult to do so by private sale,
except on the terms and conditions set forth herein. Therefore, the parties
acknowledge that a disposition of the Shares pursuant to the terms of this
Agreement is a commercially reasonable disposition. The parties further
acknowledge and agree that the determination of the Purchase Price under Section 7
is a commercially reasonable method of determining the Purchase Price and that
they will be bound by such Purchase Price determination.

 

9.                          Term. This
Agreement shall continue for as long as the MSA and any renewals thereof are in
effect.

 

10.                    Representations
and Warranties. P.C. and each of the Shareholders represent and
warrant the following:

 

10.1             No
Contravention. There is no provision of any agreement to which
P.C. or any Shareholder is a party or of any law that would be contravened by
the execution, delivery, or performance of this Agreement. There are no
outstanding or authorized options, warrants, purchase rights, subscription
rights, conversion rights, exchange rights, or other contracts or commitments
that could require the P.C. to issue, sell, or otherwise cause to become
outstanding any of its capital stock. There is no litigation nor are there any
proceedings by any public body, agency, or authority presently pending or
threatened against the P.C. or any Shareholder, the outcome of which might
materially and adversely affect the continued operations of the P.C.

 

10.2             Shares. Each
Shareholder has good title, free and clear of all claims, charges, liens,
encumbrances, restrictions, options, calls and defects of any kind or nature
whatsoever, except for the security interest granted hereby; no other person,
entity, or governmental authority has or claims any lien or other interest in
the Shares; no adverse financing statements are on file; and there is no
litigation nor are there any proceedings by any public body, agency, or
authority presently pending or threatened against any Shareholder, the outcome
of which might materially and adversely affect the Collateral.

 

10.3             Survival of
Representations and Warranties. All representations and
warranties shall survive the execution and delivery of this Agreement.

 

4

 

11.                    Affirmative
Covenants.

 

11.1             Application to
Future Shares. This Agreement shall apply to all Shares now owned
or hereafter acquired whether such acquisition be the result of purchase, stock
dividend, split-up, recapitalization or issuance by the P.C. of additional
shares of capital stock.

 

11.2             No Agency and
Defense Against Claims. Nothing in this Agreement shall make any
Shareholder an agent of Manager for any purpose whatsoever. Each Shareholder
shall defend the Shares against all claims, demands, and defenses affecting
Management Service’s security interest, regardless of merit, and shall hold
Manager harmless therefrom, including, without limitation, holding Manager
harmless from all attorneys’ fees and other litigation expenses arising out of
any such claims, demands, or defenses.

 

11.3             Disposition and
Issuances of the P.C.’s Common Stock. The P.C. shall not, and
during the term of this Agreement each Shareholder shall not cause the P.C. to
issue, sell or otherwise cause to be outstanding any additional capital stock,
except for (a) sales of such stock made to approved Shareholders; (b) the
transfer without consideration of any of the Shares to a revocable trust
created by a Shareholder, provided that any and all trustees of such trust
first agrees in writing to hold Shares so transferred subject to this
Agreement; and (c) the transfer of Shares to the Transferee as provided
herein.

 

11.4             Restriction on
Distributions. In no event shall the Current Shareholder cause
the P.C. to make distributions to any individual or entity other than pursuant
to the MSA without the express prior written consent of Manager.

 

12.                    Custody and
Handling of Collateral and Records.

 

12.1             Protection of
Secured Party’s Security Interest. Upon execution of this
Agreement, each Shareholder shall give Manager the certificate(s) representing
such Shareholder’s Shares duly endorsed in blank or, if not endorsed in blank,
each Shareholder shall give Manager a duly executed stock power in blank.

 

12.2             Restrictive
Legend. Each certificate representing Shares shall be marked with a legend
substantially in the following form:

 

THE RIGHT
TO SELL, TRANSFER OR ENCUMBER THE SHARES REPRESENTED BY THIS CERTIFICATE IS
RESTRICTED UNDER THE TERMS OF TRANSITION AGREEMENT AND STOCK PLEDGE DATED JUNE
1, 2005, TO WHICH THE P.C. IS A PARTY. THE P.C. WILL MAIL A COPY OF SAID
AGREEMENT TO ANY SHAREHOLDER WITHOUT CHARGE WITHIN FIVE (5) DAYS AFTER
RECEIPT OF WRITTEN REQUEST THEREFORE.

 

13.                    Default and
Remedies.

 

13.1             Remedies Upon
Default. Upon the occurrence of any breach of any covenant or warranty
contained in this Agreement (“Default”) by the P.C. or any or all of the
Shareholders and continuously thereafter until waived in writing, any of the
parties hereto not in breach of this Agreement shall have the right and option
to immediately send notice to all parties

 

5

 

hereto of a Shareholder
Event of Transfer or a P.C. Event of Transfer, as applicable, to cause a
transfer of Shares pursuant to Section 5 or Section 6 hereof, subject
to a subsequent determination of the Purchase Price. In the event of a Default,
Manager may exercise any other remedy available to Manager as a secured party
under law or equity. Manager shall be entitled upon any breach or threatened
breach of this Agreement to the granting of a temporary restraining order, a
temporary or permanent injunction, or any other equitable remedy which may then
be available without further notice.

 

13.2             Construction of
Rights and Remedies and Waiver of Notice and Consent.

 

(a)                     This Section 13
applies to all rights and remedies provided by this Agreement or at law or in
equity.

 

(b)                    No forbearance
in exercising any right or remedy shall operate as a waiver thereof; no
forbearance in exercising any right or remedy on any one or more occasions
shall operate as a waiver thereof on any future occasion; and no single or
partial exercise of any right or remedy shall preclude any other exercise thereof
or the exercise of any other right or remedy.

 

14.                    Miscellaneous.

 

14.1             Notices. If at any
time after the execution of this Agreement, it shall become necessary or
convenient for one of the parties to serve any notice, demand or communication
upon the other parties, such notice, demand, or communication shall be in
writing and shall be served personally, by nationally recognized overnight
courier which provides confirmation of delivery, or by depositing the same in
the United States mail, registered or certified, return receipt requested,
postage prepaid and to such address as each party may have furnished to the
other parties in writing as the place for the service of notice. Any notice so
mailed shall be deemed to have been given three (3) days after the same
has been deposited in the United States mail; when delivered if the same has
been given personally; or the next business day if the same has been delivered
to a nationally recognized overnight courier service.

 

14.2             Governing Law. This
Agreement shall be construed and interpreted under the laws of the Commonwealth
of Massachusetts.

 

14.3             Binding Effect. This
Agreement shall be binding upon the P.C., each Shareholder, the Shareholders’
personal representatives, heirs, successors, and assigns, as the case may be,
and shall be binding upon and inure to the benefit of Manager and its
successors and assigns. Neither the P.C. nor any Shareholder may assign this
Agreement.

 

14.4             Amendment. This
Agreement may be amended, but only by a written amendment signed by all parties
hereto.

 

14.5             Severabilitv. If any
provision of this Agreement or the application of any provision to any party or
circumstance shall be adjudged invalid or unenforceable to any extent, the
remainder of this Agreement and the application of the provision to any other
party or

 

6

 

circumstance shall not be
affected thereby. Each provision of this Agreement shall be valid and
enforceable to the fullest extent permitted by law.

 

14.6             Headings. The headings
in this Agreement are for convenience of reference only and shall not be used
in interpreting this Agreement.

 

14.7             Number; Gender. Where
appropriate, the number of all words in this Agreement shall be both singular
and plural and the gender of all pronouns shall be masculine, feminine, neuter,
or any combination thereof.

 

7

 

IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date first set forth above.

 

	
   

  	
  NEW ENGLAND RADIATION
  THERAPY

  MANAGEMENT SERVICES, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ David M. Koeninger

  
	
   

  	
  Name:

  	
  David M. Koeninger

  
	
   

  	
  Title:

  	
  VP

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  MASSACHUSETTS ONCOLOGY
  SERVICES, P.C.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Daniel E. Dosoretz

  
	
   

  	
  Name:

  	
   

  
	
   

  	
  Title:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Daniel E. Dosoretz

  
	
   

  	
  Daniel
  E. Dosoretz, M.D.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  /s/ Michael Katin

  
	
   

  	
  Michael Katin, M.D.

  

 

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]